Nestlé bets on AI-powered food development and sees potential in the weight-loss drug market

The company is closely monitoring developments and examining which foods are particularly suitable for people taking such medications. In Nestlé's view, this includes products with higher protein content or adapted nutrient compositions to meet the changed needs during weight reduction.

Weight-loss injection market growing rapidly

Amanda Avery, a nutrition scientist at the University of Nottingham, fundamentally confirms the need. People undergoing GLP-1 therapy often have a changed appetite and special nutritional requirements, she said. Nestlé says it is also working with external research institutions to deepen the scientific basis for corresponding products.

Internally, Nestlé uses the AI platform to identify patterns in study data that would be difficult to detect using conventional methods. According to the company, the system can generate suggestions for formulations, which are then tested in laboratories and pilot facilities. This significantly shortens the time from idea to finished product, Palzer said.

The market for weight-loss drugs has developed dynamically in recent years. The preparations, originally developed for the treatment of diabetes, are increasingly being prescribed for weight reduction as well. Industry analysts expect the number of users worldwide to continue to rise – opening up new target groups for food companies like Nestlé.

Strategic observation rather than concrete plans

At the same time, Nestlé faces the challenge that consumers taking medication have different expectations regarding taste, portion size, and nutritional value. Palzer sees a clear competitive advantage here through the use of AI: The technology makes it possible to react very quickly to new findings and develop tailored products.

The company emphasizes that its considerations regarding the weight-loss drug market constitute a strategic observation. No concrete products for this target group have been announced to date. Nestlé wants to first deepen the scientific basis and then decide which categories – from snacks to meal replacements – are particularly suitable.

Outlook: Research collaborations to be expanded

Market observers see the combination of AI-powered development and a focus on the weight-loss drug market as a logical next step for the group. The food industry as a whole is in a state of transformation, as consumption habits are changing due to medical innovations. Nestlé positions itself, by its own account, as a pioneer that wants to actively shape this development.

For the coming months, Palzer announced that the "Food Genie" AI platform will be further expanded. Collaboration with research institutions such as the University of Nottingham is also to be intensified in order to scientifically substantiate the effectiveness of accompanying nutritional concepts during the use of weight-loss injections.

Industry experts view the strategy as a sign that large food companies increasingly see the interface between medicine and nutrition as a growth field. Should Nestlé actually launch products for users of weight-loss injections on a large scale, this could sustainably change the competitive landscape in several categories.